There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
C-reactive protein (CRP) is a sensitive marker of inflammation, and elevated levels
have been associated with future risk of myocardial infarction (MI). However, whether
measurement of CRP adds to the predictive value of total cholesterol (TC) and HDL
cholesterol (HDL-C) in determining risk is uncertain.
Among 14916 apparently healthy men participating in the Physicians' Health Study,
baseline levels of CRP, TC, and HDL-C were measured among 245 study subjects who subsequently
developed a first MI (cases) and among 372 subjects who remained free of cardiovascular
disease during an average follow-up period of 9 years (controls). In univariate analyses,
high baseline levels of CRP, TC, and TC:HDL-C ratio were each associated with significantly
increased risks of future MI (all P values <0.001). In multivariate analyses, models
incorporating CRP and lipid parameters provided a significantly better method to predict
risk than did models using lipids alone (all likelihood ratio test P values <0.003).
For example, relative risks of future MI among those with high levels of both CRP
and TC (RR=5.0, P=0.0001) were greater than the product of the individual risks associated
with isolated elevations of either CRP (RR=1.5) or TC (RR=2.3). In stratified analyses,
baseline CRP level was predictive of risk for those with low as well as high levels
of TC and the TC:HDL-C ratio. These findings were virtually identical in analyses
limited to nonsmokers and after control for other cardiovascular risk factors.
In prospective data from a large cohort of apparently healthy men, baseline CRP level
added to the predictive value of lipid parameters in determining risk of first MI.
The Physicians' Health Study is a randomized, double-blind, placebo-controlled trial designed to determine whether low-dose aspirin (325 mg every other day) decreases cardiovascular mortality and whether beta carotene reduces the incidence of cancer. The aspirin component was terminated earlier than scheduled, and the preliminary findings were published. We now present detailed analyses of the cardiovascular component for 22,071 participants, at an average follow-up time of 60.2 months. There was a 44 percent reduction in the risk of myocardial infarction (relative risk, 0.56; 95 percent confidence interval, 0.45 to 0.70; P less than 0.00001) in the aspirin group (254.8 per 100,000 per year as compared with 439.7 in the placebo group). A slightly increased risk of stroke among those taking aspirin was not statistically significant; this trend was observed primarily in the subgroup with hemorrhagic stroke (relative risk, 2.14; 95 percent confidence interval, 0.96 to 4.77; P = 0.06). No reduction in mortality from all cardiovascular causes was associated with aspirin (relative risk, 0.96; 95 percent confidence interval, 0.60 to 1.54). Further analyses showed that the reduction in the risk of myocardial infarction was apparent only among those who were 50 years of age and older. The benefit was present at all levels of cholesterol, but appeared greatest at low levels. The relative risk of ulcer in the aspirin group was 1.22 (169 in the aspirin group as compared with 138 in the placebo group; 95 percent confidence interval, 0.98 to 1.53; P = 0.08), and the relative risk of requiring a blood transfusion was 1.71. This trial of aspirin for the primary prevention of cardiovascular disease demonstrates a conclusive reduction in the risk of myocardial infarction, but the evidence concerning stroke and total cardiovascular deaths remains inconclusive because of the inadequate numbers of physicians with these end points.
Increased levels of certain hemostatic factors may play a part in the development of acute coronary syndromes and may be associated with an increased risk of coronary events in patients with angina pectoris. We conducted a prospective multicenter study of 3043 patients with angina pectoris who underwent coronary angiography and were followed for two years. Base-line measurements included the concentrations of selected hemostatic factors indicative of a thrombophilic state or endothelial injury. The results were analyzed in relation to the subsequent incidence of myocardial infarction or sudden coronary death. After adjustment for the extent of coronary artery disease and other risk factors, an increased incidence of myocardial infarction or sudden death was associated with higher base-line concentrations of fibrinogen (mean +/- SD, 3.28 +/- 0.74 g per liter in patients who subsequently had coronary events, as compared with 3.00 +/- 0.71 g per liter in those who did not; P = 0.01), von Willebrand factor antigen (138 +/- 49 percent vs. 125 +/- 49 percent, P = 0.05), and tissue plasminogen activator (t-PA) antigen (11.9 +/- 4.7 ng per milliliter vs. 10.0 +/- 4.2 ng per milliliter, P = 0.02). The concentration of C-reactive protein was also directly correlated with the incidence of coronary events (P = 0.05), except when we adjusted for the fibrinogen concentration. In patients with high serum cholesterol levels, the risk of coronary events rose with increasing levels of fibrinogen and C-reactive protein, but the risk remained low even given high serum cholesterol levels in the presence of low fibrinogen concentrations. In patients with angina pectoris, the levels of fibrinogen, von Willebrand factor antigen, and t-PA antigen are independent predictors of subsequent acute coronary syndromes. In addition, low fibrinogen concentrations characterize patients at low risk for coronary events despite increased serum cholesterol levels. Our data are consistent with a pathogenetic role of impaired fibrinolysis, endothelial-cell injury, and inflammatory activity in the progression of coronary artery disease.
[1
]From the Divisions of Preventive Medicine (P.M.R., R.J.G., C.H.H.) and Cardiovascular
Diseases (P.M.R.), Department of Medicine, Brigham and Women’s Hospital, and the Department
of Ambulatory Care and Prevention (C.H.H.), Harvard Medical School, Boston, Mass.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.